Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
about
Effect of iprindole on the metabolism of trimipramine in the rat.Absence of effect of stimulants on the phamacokinetics of desipramine in children.Polymorphism in the metabolism of drugs, including antidepressant drugs: comments on phenotypingSSRI-induced extrapyramidal side-effects and akathisia: implications for treatment.Pindolol augmentation of antidepressants: a review and rationale.The SSRIs: advantages, disadvantages and differences.Inhibitors of alprazolam metabolism in vitro: effect of serotonin-reuptake-inhibitor antidepressants, ketoconazole and quinidineCarbamazepine-hypersensitivity: assessment of clinical and in vitro chemical cross-reactivity with phenytoin and oxcarbazepine.Clinical implications of drug interactions with coxibs.Molecular heterogeneity of the XbaI defined 44kb allele of the CYP2D locus within the Caucasian population.Increasing relevance of pharmacogenetics of drug metabolism in clinical practice.Differential metabolism of alprazolam by liver and brain cytochrome (P4503A) to pharmacologically active metabolite.Pharmacology of 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors (statins), including rosuvastatin and pitavastatin.Stereochemistry and drug efficacy and development: relevance of chirality to antidepressant and antipsychotic drugs.Over-the-counter medications in cardiac transplant recipients: guidelines for use.Pharmacogenetics: Part I.Genetic aspects of drug disposition and therapeutics.Role of efflux pumps and metabolising enzymes in drug delivery.Alternative splicing within the human cytochrome P450 superfamily with an emphasis on the brain: The convolution continues.Species differences in metabolism and pharmacokinetics: are we close to an understanding?Pharmacogenetics of drug oxidation via cytochrome P450 (CYP) in the populations of Denmark, Faroe Islands and Greenland.The effect of parenteral nutrition on hepatic cytochrome P-450.Sources of prediction error when using a Bayesian method to evaluate nortriptyline serum concentrations.Inter-ethnic comparisons of the pharmacokinetics of the HMG-CoA reductase inhibitor cerivastatin.Do predictive parameters exist for therapy with duloxetine in women with stress urinary incontinence?Flecainide for the treatment of chronic neuropathic pain: a Phase II trial.Pharmacogenetics: part I: Perspective. 1992.Pharmacogenetics: part II: Perspective. 1992.In vitro prediction of the terfenadine-ketoconazole pharmacokinetic interaction.Simultaneous determination of metoprolol and α-hydroxymetoprolol in human plasma using excitation-emission matrix fluorescence coupled with second-order calibration methods.Changes in the metabolism of three model substrates catalysed by different P450 isozymes when administered as a cocktail to the carbon tetrachloride-intoxicated rat.The effect of sepsis during parenteral nutrition on hepatic microsomal function in rats.
P2860
Q24535646-6CBEBC24-C328-4B54-89B5-13B66FFE2082Q33677560-547179A4-184D-4309-A9DB-609224D7A99BQ33921325-991E60DB-EA69-4D1A-9490-BC8570B0B472Q34067137-80C9DCDF-7C2A-46CA-ABE4-31D89F1AB015Q34143604-925D15C2-AD35-4267-8346-028ED2CAA7E6Q34251176-3218A1BF-B2D9-49D1-A9DB-83CE06533609Q34346469-5AE57C33-BFE4-4A1D-944D-A336E622AF18Q34358782-AC61C4A9-5FC7-4C4C-9F37-443A46A3D756Q34401549-D3BAF242-1C12-44BD-A733-944D4A7E42CFQ34403562-8DCDA8C6-2D41-427A-8CAD-E723C89DF968Q34447018-3F5F9E29-90E7-45F1-8612-D4C54F3778C7Q34526540-F37E75CD-8F51-46B2-AE32-622D4E2A1DFBQ34773911-2495E188-C4F9-4E60-940D-F074C8C8C1CDQ35054997-B9190A02-CABE-416B-9AA3-C2AC240362E0Q35276052-2023264F-7F8B-41FA-B4E2-30A9E8D44BB1Q36215632-B7C9D758-1236-4A69-B785-99841BEB6FAAQ36244452-101F9CC1-D31C-40F1-BFF2-2CBBC1DBFCB8Q36316872-AED3F753-7DA1-448E-B981-FE0A89088955Q36544917-D40C8A4B-A729-47CB-95C4-FE5C27A0EDA6Q37437853-D783B9B2-50FE-477E-94F5-A3145F4A17A6Q38365410-AEA144B0-39E5-4471-96B5-C5D6F017DF3BQ40565626-D089FCDF-679C-414F-A1D8-16B162438AF3Q41024547-55B3AB67-458B-49E1-A167-9AA54D7B3475Q41864942-340E19FB-9D68-4AD6-A719-34740C41461EQ45902947-14BF7F77-B627-4783-BE2F-3BBB3E7AED12Q46855528-7620EF9A-86F6-4F45-BF31-70DDA2F36EF1Q48543712-209BD010-E060-430C-8F33-DF75399261CAQ48543727-75907717-FCDD-4371-B490-D8FB888924B3Q49166540-45361024-66AF-40F0-9688-350E743AC04EQ51291298-BC3A7E5B-4052-487F-8AFD-925652DFDCD1Q51590540-554BA6CD-D958-49D7-9707-5EEC1CEE26D6Q54538444-D0435280-E318-4389-BFDF-8DDE42E7DB3A
P2860
Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Recent developments in hepatic ...... for clinical pharmacokinetics.
@en
Recent developments in hepatic ...... for clinical pharmacokinetics.
@nl
type
label
Recent developments in hepatic ...... for clinical pharmacokinetics.
@en
Recent developments in hepatic ...... for clinical pharmacokinetics.
@nl
prefLabel
Recent developments in hepatic ...... for clinical pharmacokinetics.
@en
Recent developments in hepatic ...... for clinical pharmacokinetics.
@nl
P1476
Recent developments in hepatic ...... for clinical pharmacokinetics.
@en
P2093
P304
P356
10.2165/00003088-199018030-00004
P577
1990-03-01T00:00:00Z
P6179
1009377721